| |
|
|
|
Xtalks, Online
2025-04-14
Vascular phenotyping has emerged as an important tool in advancing our understanding of chronic diseases. By providing non-invasive, digital biomarkers of vascular function phenotyping enables an early identification of subclinical disease, and a more precise approach to risk stratification and therapeutic effectiveness. Key modalities, including arterial stiffness indices, endothelial function assessments and advanced imaging techniques, offer insights from early vascular changes through the spectrum of vascular disease and cardiovascular events including myocardial infarction and stroke.
Incorporating vascular phenotyping into clinical trials enhances the mechanistic understanding of investigational therapies, facilitates personalized treatment approaches, and strengthens the predictive value of trial outcomes. It is particularly important in studies targeting cardiovascular, respiratory, renal, and metabolic diseases as well as in women’s health and in various ethnicities where vascular changes is both a mediator and a marker of disease progression.
As precision medicine continues to evolve, vascular phenotyping serves as an indispensable bridge between research and clinical application, ultimately improving patient care and therapeutic innovation.
Register for this webinar today to explore how vascular phenotyping can be included in the design of clinical trials, and how new digital health technologies that capture biomarkers of vascular disease can be used to determine the efficacy of emerging therapies.
Keywords: Clinical Trials, Cardiovascular Disease, Drug Development, Precision Medicine, Clinical Research, Cardiovascular, Cardiovascular Health, Regulatory, Cardiovascular Clinical Trials, Quality
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Dr. Sanjeev Bhavnani, MD, FACC, Chief Clinical Officer, Cardiex
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-04-14
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|